$AVAI

AVAI BIO, INC.

CIK:0001740797|SEC Filings

Consolidated Statements of Operations - USD ($)	3 Months Ended
Consolidated Statements of Operations - USD ($)	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
REVENUE
OPERATING EXPENSES
Amortization Expense	5,244	6,518
Consulting Services	105,000	64,910
General and Administrative Expenses	176,480	213,886
Marketing Expenses	100,750	154,190
Professional Fees	32,309	48,085
TOTAL OPERATING EXPENSES	419,783	487,589
OTHER INCOME (EXPENSES)
Discount on Convertible Note	(47,100)
Interest Expense, Net	(60,615)
Loss on Disposal of Subsidiary	(24,543)
NET LOSS FROM OPERATIONS	(552,041)	487,589
PROVISION FOR INCOME TAXES
NET LOSS	(552,041)	487,589
COMPREHENSIVE LOSS	$ (552,041)	$ 487,589
NET LOSS PER SHARE: BASIC AND DILUTED	$ (0.00)	$ (0.00)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	153,916,565	137,462,534

Consolidated Statement of Cash Flows - USD ($)	3 Months Ended
Consolidated Statement of Cash Flows - USD ($)	Jun. 30, 2026	Jun. 30, 2025
OPERATING ACTIVITIES
Net Loss	$ (552,041)	$ (487,589)
Amortization	5,244	6,518
Prepaid Expenses	(4,500)	1,930
Accounts Payable	137,039	238,798
Net cash used in Operating Activities	(414,258)	(240,343)
INVESTING ACTIVITIES
API Acquisition	(58,600)
Net cash used in Investing Activities	(58,600)
FINANCING ACTIVITIES
Additional Paid in Capital	143,925	59,852
Capital Stock	705	148
Convertible Notes Payable	224,589	(100,464)
Due from Subsidiaries	(100,757)
Loan from Related Parties	58,552	119,816
Loan Payable	206,285	90,000
Net cash provided by Financing Activities	533,299	169,352
Net cash increase (decrease) for period	60,441	(70,991)
Cash at beginning of period	23,145	81,053
Cash at end of period	$ 83,586	$ 10,062

Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Mar. 31, 2026
Current Assets
Cash and Cash Equivalents	$ 83,586	$ 23,145
Loan Receivable	60,095	60,095
Prepaid Expenses	10,600	6,100
Total Current Assets	154,281	89,340
Other Assets
Intangible Assets, Net (Note 6)	158,898	105,542
Due from Subsidiaries	478,571	377,814
Total Other Assets	637,469	483,356
TOTAL ASSETS	791,750	572,696
Current Liabilities
Accounts Payable	1,729,921	1,592,882
Convertible Notes Payable (Note 8)	725,138	500,549
Loan Payable - Related Parties (Note 7)	802,972	744,420
Loan Payable (Note 8)	756,285	550,000
Total Current Liabilities	4,014,316	3,387,851
Total Liabilities	4,014,316	3,387,851
Stockholders’ Deficit
Preferred stock, $0.001 par value, 20,000,000 shares authorized; 11,300,000 and 11,300,000 common shares issued and outstanding respectively (Note 9)	11,300	11,300
Preferred stock Series A, $0.001 par value, 5,000 shares authorized; 3,050 and 3,050 shares issued and outstanding, respectively (Note 9)	15,250	15,250
Common stock, $0.001 par value, 500,000,000 shares authorized; 153,916,565 and 153,211,252 common shares issued and outstanding respectively (Note 9)	153,917	153,212
Additional Paid in Capital	3,017,027	2,873,102
Accumulated Deficit	(6,420,060)	(5,868,019)
Total Stockholders’ Deficit	(3,222,566)	(2,815,155)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 791,750	$ 572,696